Statements (63)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
osmotic diuretic
|
| gptkbp:approves |
gptkb:1956
gptkb:FDA |
| gptkbp:brand |
gptkb:Osmitrol
|
| gptkbp:clinical_trial |
critical care
ophthalmology neurosurgery urology |
| gptkbp:contraindication |
severe dehydration
pulmonary edema active intracranial bleeding anuria cardiac failure severe renal disease |
| gptkbp:dissolved |
soluble in water
slightly soluble in alcohol |
| gptkbp:formulation |
sterile solution
|
| gptkbp:has_expansion |
approximately 300 m Osm/ L
|
| https://www.w3.org/2000/01/rdf-schema#label |
Mannitol Injection
|
| gptkbp:indication |
gptkb:sneaker
cerebral edema prevention of acute kidney injury |
| gptkbp:ingredients |
mannitol
C6 H14 O6 |
| gptkbp:is_compatible_with |
gptkb:Sodium_Chloride
gptkb:Company gptkb:Aminophylline Dextrose Calcium salts |
| gptkbp:is_monitored_by |
blood pressure
renal function fluid balance serum electrolytes |
| gptkbp:is_used_for |
promoting diuresis
reducing intracranial pressure treating oliguric renal failure |
| gptkbp:level |
5.0 to 7.0
|
| gptkbp:lifespan |
approximately 100 minutes
|
| gptkbp:manager |
intravenous
|
| gptkbp:manufacturer |
various pharmaceutical companies
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Australia gptkb:India gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:packaging |
vials
|
| gptkbp:produced_by |
IV infusion
bolus injection |
| gptkbp:rounds |
renal
|
| gptkbp:side_effect |
headache
nausea electrolyte imbalance confusion dehydration fluid overload hypotension thrombophlebitis |
| gptkbp:storage |
room temperature
protected from light |
| gptkbp:weight |
182.17 g/mol
|
| gptkbp:bfsParent |
gptkb:Mannitol
|
| gptkbp:bfsLayer |
5
|